


Detecting bowel cancer without a stool test

January 24 2024



Schematic of orally-delivered EcN probiotic engineered to lyse and produce immunotherapeutic proteins in situ (top) and schematic of dosing regimen (bottom). Credit: *Nature Communications* (2024). DOI: 10.1038/s41467-024-44776-4

An international team of researchers from Adelaide and the United States has opened the door to non-stool-based bowel cancer detection by



showing that a probiotic bacteria already being used to treat gut disorders can be engineered to reveal the presence of early tumors.

Published in *Nature Communications* and led by Associate Professor Susan Woods, Dr. Dan Worthley and Ph.D. candidate Georgette Radford from SAHMRI and the University of Adelaide, in partnership with Associate Professor Tal Danino at Columbia University, <u>the study</u> focused on the bacteria Escherichia coli Nissle. This strain was first isolated from the gut of a German soldier in 1917 by German physician, Alfred Nissle.

When <u>dysentery</u> was rife in the trenches during WW1, Nissle studied the microbiome of one man who appeared to be immune to the disease and found the unique strain. It was later proven to block and fight <u>bad</u> <u>bacteria</u>, and now has a long history of safe use in people.

Researchers recently discovered another quirk of Escherichia coli Nissle; rather than live in normal tissue, it prefers to live in tumors when they're present in the gut and will actively seek them out.

"Our study shows that after oral dosing, these bacteria selectively live in the gut in both the benign precursor lesions to <u>bowel cancer</u>, called polyps, and also bowel cancers," Radford said.

"We've taken advantage of this bacteria's natural gravitation towards tumors and engineered it to release molecules that illuminate early cancers."

Woods says the method could be used to diagnose cancer early and non-invasively.

"Once the bacteria locates the tumor it releases a marker that we can then detect in urine, which shows cancer is present," Woods said.



"In the future, we're aiming to be able to detect this marker in a blood test."

The research team is confident the <u>bacteria</u> can also be manipulated to deliver therapeutic treatment directly to the tumor site, providing another option to treat early cancers, while drastically reducing current side effects that come with putting drugs in the body.

"We were excited to see that the tumor-homing capability of these <u>probiotic bacteria</u> may also occur in people, just as in our experimental models," Worthley said.

More information: Candice R. Gurbatri et al, Engineering tumorcolonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia, *Nature Communications* (2024). <u>DOI:</u> <u>10.1038/s41467-024-44776-4</u>

Provided by South Australian Health and Medical Research Institute (SAHMRI)

Citation: Detecting bowel cancer without a stool test (2024, January 24) retrieved 28 April 2024 from <u>https://medicalxpress.com/news/2024-01-bowel-cancer-stool.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.